CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
5 results
Search Results
Now showing 1 - 5 of 5
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis(2023) ;Wilson Bautista-Molano ;Daniel G. Fernández-Ávila ;María Lorena Brance ;María Gabriela Ávila PedrettiRuben Burgos-Vargas3Scopus© Citations 45 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Cardiovascular events risk in patients with systemic autoimmune diseases: a prognostic systematic review and meta-analysis(2023); ;Leticia González ;Juan Francisco Bulnes ;Marta RoqueScopus© Citations 21 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Approach to the Patient with Axial Spondyloarthritis and Suspected Inflammatory Bowel Disease(2020); ;María Paz Poblete De La FuenteElisa Catalina Parra Cancino3 1Scopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study(2021) ;Clementina López-Medina ;Anna Molto ;Joachim Sieper ;Tuncay DuruözUta Kiltz<jats:sec><jats:title>Objectives</jats:title><jats:p>To characterise peripheral musculoskeletal involvement in patients with spondyloarthritis (SpA) including psoriatic arthritis (PsA), across the world.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Cross-sectional study with 24 participating countries. Patients with a diagnosis of axial SpA (axSpA), peripheral SpA (pSpA) or PsA according to their rheumatologist were included. The investigators were asked which diagnosis out of a list of six (axSpA, PsA, pSpA, inflammatory bowel disease-associated SpA, reactive arthritis or juvenile SpA (Juv-SpA)) fitted the patient best. Peripheral manifestations (ie, peripheral joint disease, enthesitis, dactylitis and root joint disease), their localisation and treatments were evaluated.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 4465 patients were included (61% men, mean age 44.5 years) from four geographic areas: Latin America (n=538), Europe plus North America (n=1677), Asia (n=975) and the Middle East plus North Africa (n=1275). Of those, 78% had ever suffered from at least one peripheral musculoskeletal manifestation; 57% had peripheral joint disease, 44% had enthesitis and 15% had dactylitis. Latin American had far more often peripheral joint disease (80%) than patients from other areas. Patients with PsA had predominantly upper limb and small joint involvement (52%).</jats:p><jats:p>Hip and shoulder involvement was found in 34% of patients. The prevalence of enthesitis ranged between 41% in patients with axSpA and 65% in patients with Juv-SpA. Dactylitis was most frequent among patients with PsA (37%).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>These results suggest that all peripheral features can be found in all subtypes of SpA, and that differences are quantitative rather than qualitative. In a high proportion of patients, axial and peripheral manifestations coincided. These findings reconfirm SpA clinical subtypes are descendants of the same underlying disease, called SpA.</jats:p></jats:sec>2Scopus© Citations 103 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview(2020) ;Rodrigo A. Valenzuela ;Iván Flores ;Beatriz Urrutia ;Francisca FuentesPablo E. SabatScopus© Citations 28 2